Impella

Type: Product
Name: Impella
First reported Aug 26 2014 - Updated Aug 26 2014 - 1 reports

ABIOMED Makes a Move: Up 1.8%...

ABIOMED (NASDAQ:ABMD) is one of today's notable stocks on the rise, up 1.8% to $25.56. The Dow is up 0.2% to 17,118 and the S&P is currently trading fractionally higher to 2,000.Potential upside of 11.2% exists for ABIOMED, based on a current level of ... [Published Financial News Network online - Aug 26 2014]
First reported Aug 20 2014 - Updated Aug 20 2014 - 1 reports

9.9% Return Seen to Date on SmarTrend ABIOMED Call (ABMD)

Written on Wed, 08/20/2014 - 11:31amBy Shiri GuptaSmarTrend identified an Uptrend for ABIOMED ( NASDAQ:ABMD ) on June 6th, 2014 at $23.28. In approximately 3 months, ABIOMED has returned 9.90% as of today's recent price of $25.58.In the past 52 weeks, ... [Published Comtex SmarTrend - Aug 20 2014]
First reported Aug 16 2014 - Updated Aug 16 2014 - 1 reports

New device brings relief to ailing hearts at Riverview

Riverview Regional Medical Center’s Heart and Vascular team performed Etowah County’s first Abiomed Impella 2.5 procedure on Wednesday.Dr. BJ Patel, a cardiologist, performed the procedure. The technology is aimed at providing fast, effective relief for ... [Published Gadsden Times - Aug 16 2014]
First reported Aug 12 2014 - Updated Aug 12 2014 - 1 reports

Abiomed inks extension in Impella probe

by Abiomed says it struck a deal to extend the statute of limitations on any charges that might arise from a U.S. Justice Dept. probe of the marketing for its Impella heart pump and raised its estimate of the legal fees from the investigation.Abiomed ... [Published MassDevice - Aug 12 2014]
First reported Aug 05 2014 - Updated Aug 05 2014 - 1 reports

Forbion Capital to sell Santaris Pharma to Roche for up to $450 mln

Forbion Capital Partners has sold biopharmaceutical company Santaris Pharma A/S for $450 million to Roche . The deal is structured with an upfront cash payment of $250 million and additional contingent payments of up to $200 million based on achievement ... [Published PE Hub Blog - Aug 05 2014]
First reported Aug 04 2014 - Updated Aug 04 2014 - 3 reports

Abiomed Falls, Sees Flat Fiscal Q1 Loss and Miss Estimates - Analyst Blog

Shares of Abiomed Inc. ( ABMD ) dipped roughly 4.0% after posting a loss of $1.7 million or 4 cents per share for the first quarter of fiscal 2015 that was flat compared with the year-ago quarter. With this, the company missed the Zacks Consensus Estimate ... [Published Zacks.com - Aug 04 2014]
First reported Jul 31 2014 - Updated Jul 31 2014 - 1 reports

Triumphs and Regrets of an Early Adopter

Editor's Note: On July 1, Dr. Bilazarian's practice was acquired and he became an employed physician. To reflect this change, his series will be renamed Practitioner's Corner.To download the slides used in Dr. Bilazarian's presentation, click here .Seth ... [Published General Medicine eJournal - Jul 31 2014]
First reported Jul 31 2014 - Updated Jul 31 2014 - 3 reports

Abiomed's (ABMD) CEO Michael Minogue on Q1 2015 Results - Earnings Call Transcript

OperatorGood day, ladies and gentlemen. Welcome to the Abiomed, Inc. Q1 2015 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that ... [Published Seeking Alpha - Jul 31 2014]
First reported Jul 25 2014 - Updated Jul 26 2014 - 1 reports

US Federal Business Opportunity: Department of the Air Force: Impella Pump

Agency: Department of the Air ForceOffice: Air Education and Training Command Location: Keesler AFB, 81st Contracting SquadronDate you need to respond by: 29-July-2014Solicitation Number: FA3010-14-T-0052 Naics code: 334510 Computer and Electronic Product ... [Published ITbriefing - Jul 25 2014]
First reported Jul 22 2014 - Updated Jul 22 2014 - 1 reports

ABIOMED Makes a Move: Up 2.8%...

One of today's stocks on the move is ABIOMED (NASDAQ:ABMD), up 2.8% to $25.99. The Dow Jones Industrial Average is now trading 0.3% higher to 17,110 and the S&P is trading 0.5% higher to 1,985.Abiomed, Inc. provides medical devices in circulatory support ... [Published Financial News Network online - Jul 22 2014]
First reported Jul 09 2014 - Updated Jul 10 2014 - 1 reports

Forbion Capital Partners’ arGEN-X completes IPO

Clinical-stage biopharmaceutical company arGEN-X has completed its IPO. arGEN-X is a Forbion Capital Partners ‘ portfolio company. PRESS RELEASE Forbion Capital Partners, the leading Dutch Venture Capital firm investing in world-class healthcare ... [Published PE Hub Blog - Jul 09 2014]

Quotes

"The investigation is ongoing; however, the company is unable to predict the ultimate outcome or determine whether a liability has been incurred or make an estimate of the reasonably possible liability, if any, that could result from any unfavorable outcome associated with this inquiry" Abiomed said
...One way to help patients and assuage their concern about adopting new therapies when we decide not to adopt is to say something like, "I know you may have heard about this new therapy (drugs or a device), but I don't recommend it." That helps patients know that we've considered it and are making a conscious decision
"We are reducing the timeline range for a panel and PMA approval by 2 months for a projected approval by March 2015, based on progress and interaction with the FDA" Abiomed spokeswoman Aimee Genzler told MassDevice.com this morning via email
...double digits for 19 straight quarters year over year," said Michael R Minogue, Chairman President and ChiefChief Executive Officer of Abiomed. "This first quarter is really marked by our significant progress on execution of our strategic plans for regulatory approvals and intellectual property advantage."

More Content

All (24) | News (16) | Reports (0) | Blogs (3) | Audio/Video (0) | Fact Sheets (0) | Press Releases (5)
sort by: Date | Relevance
Abiomed, Inc. (ABMD) - Product Pipeline Analysi... [Published MarketResearch.com - 17 hours ago]
ABIOMED Makes a Move: Up 1.8%... [Published Financial News Network online - Aug 26 2014]
Abiomed, Inc. (ABMD) - Product Pipeline Analysi... [Published Research and Markets - Aug 22 2014]
9.9% Return Seen to Date on SmarTrend ABIOMED C... [Published Comtex SmarTrend - Aug 20 2014]
New device brings relief to ailing hearts at Ri... [Published Gadsden Times - Aug 16 2014]
Abiomed inks extension in Impella probe [Published MassDevice - Aug 12 2014]
Forbion Capital to sell Santaris Pharma to Roch... [Published PE Hub Blog - Aug 05 2014]
Abiomed Falls, Sees Flat Fiscal Q1 Loss and Mis... [Published Zacks.com - Aug 04 2014]
Abiomed Falls, Sees Flat Fiscal Q1 Loss and Mis... [Published Yahoo! Finance - Aug 04 2014]
ABIOMED Has Returned 9.7% Since SmarTrend Recom... [Published Comtex SmarTrend - Aug 04 2014]
Triumphs and Regrets of an Early Adopter [Published General Medicine eJournal - Jul 31 2014]
Abiomed's (ABMD) CEO Michael Minogue on Q1 2015... [Published Seeking Alpha - Jul 31 2014]
Abiomed expects FDA nod for Impella sooner than... [Published MassDevice - Jul 31 2014]
Abiomed Announces First Quarter Fiscal 2015 Rev... [Published Individual.com - Jul 31 2014]
US Federal Business Opportunity: Department of ... [Published ITbriefing - Jul 25 2014]
ABIOMED Makes a Move: Up 2.8%... [Published Financial News Network online - Jul 22 2014]
Forbion Capital Partners’ arGEN-X completes IPO [Published PE Hub Blog - Jul 09 2014]
Abiomed Surpasses 20,000 Impella Patients in th... [Published GlobeNewswire: Advertising News - Jun 03 2014]
Abiomed Receives Continuous Access Protocol (CA... [Published GlobeNewswire: Advertising News - May 21 2014]
Abiomed's Impella(R) Technology Showcased at Eu... [Published GlobeNewswire: Acquisitions News - May 19 2014]
Impella Maintains Existing Diagnosis Related Gr... [Published GlobeNewswire: Acquisitions News - Mar 21 2014]
Abiomed Completes Patient Enrollment in RECOVER... [Published GlobeNewswire: Acquisitions News - Mar 20 2014]
Forbion Announces Closing of Public Offering of... [Published BioPortfolio - Feb 20 2014]
Forbion Capital-backed uniQure completes IPO [Published PE Hub Blog - Feb 13 2014]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Forbion Capital to sell Santaris Pharma to Roch... [Published PE Hub Blog - Aug 05 2014]
Forbion Capital Partners has sold biopharmaceutical company Santaris Pharma A/S for $450 million to Roche . The deal is structured with an upfront cash payment of $250 million and additional contingent payments of up to $200 million based on achievement ...
Forbion Capital Partners’ arGEN-X completes IPO [Published PE Hub Blog - Jul 09 2014]
Clinical-stage biopharmaceutical company arGEN-X has completed its IPO. arGEN-X is a Forbion Capital Partners ‘ portfolio company. PRESS RELEASE Forbion Capital Partners, the leading Dutch Venture Capital firm investing in world-class healthcare ...
Forbion Capital-backed uniQure completes IPO [Published PE Hub Blog - Feb 13 2014]
Forbion Capital Partners -backed uniQure , which develops gene therapy products, has completed an initial public offering at a price of $17 per share on the NASDAQ . Jefferies and Leerink Partners acted as joint book-running managers and Piper ...
1

Press Releases

sort by: Date | Relevance
Abiomed Surpasses 20,000 Impella Patients in th... [Published GlobeNewswire: Advertising News - Jun 03 2014]
Abiomed Receives Continuous Access Protocol (CA... [Published GlobeNewswire: Advertising News - May 21 2014]
Abiomed's Impella(R) Technology Showcased at Eu... [Published GlobeNewswire: Acquisitions News - May 19 2014]
Impella Maintains Existing Diagnosis Related Gr... [Published GlobeNewswire: Acquisitions News - Mar 21 2014]
Abiomed Completes Patient Enrollment in RECOVER... [Published GlobeNewswire: Acquisitions News - Mar 20 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.